메뉴 건너뛰기




Volumn 110, Issue 5, 2015, Pages 770-771

Combination therapy with sorafenib and radiofrequency ablation for hepatocellular carcinoma: A glimmer of light after the storm trial¿

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

EID: 84928887852     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.80     Document Type: Letter
Times cited : (12)

References (5)
  • 1
    • 84925223212 scopus 로고    scopus 로고
    • Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: A multicenter retrospective cohort study
    • Feng X, Xu R, Du X et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol 2014 ; 109 : 1891-9.
    • (2014) Am J Gastroenterol , vol.109 , pp. 1891-1899
    • Feng, X.1    Xu, R.2    Du, X.3
  • 2
    • 84883855857 scopus 로고    scopus 로고
    • Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma
    • Li Y, Zheng YB, Zhao W et al. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. Med Oncol 2013 ; 30 : 730.
    • (2013) Med Oncol , vol.30 , pp. 730
    • Li, Y.1    Zheng, Y.B.2    Zhao, W.3
  • 3
    • 84986903157 scopus 로고    scopus 로고
    • Hepatocellular carcinoma: Concomitant sorafenib promotes necrosis after radiofrequency ablation-propensity score matching analysis
    • Fukuda H, Numata K, Moriya S et al. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation-propensity score matching analysis. Radiology 2014 ; 272 : 598-604.
    • (2014) Radiology , vol.272 , pp. 598-604
    • Fukuda, H.1    Numata, K.2    Moriya, S.3
  • 4
    • 84907023733 scopus 로고    scopus 로고
    • STORM: A phase III randomized, doubleblind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)
    • Bruix J, Takayama T, Mazzaferro V et al. STORM: A phase III randomized, doubleblind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol 2014 ; 32 : 5s-(suppl; abstr 4006).
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Bruix, J.1    Takayama, T.2    Mazzaferro, V.3
  • 5
    • 79958704133 scopus 로고    scopus 로고
    • An introduction to propensity score methods for reducing the effects of confounding in observational studies
    • Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011 ; 46 : 399-424.
    • (2011) Multivariate Behav Res , vol.46 , pp. 399-424
    • Austin, P.C.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.